Histide™ is a biotech intellectual property platform company pioneering a new class of non-mutagenic extracellular therapeutic agents called Cell Recoding Molecules™ (CRM™). This innovative platform builds on Histide’s expertise in the mechanisms underlying the cell’s microenvironmental sensing and signal transduction processes. The CRM™ promote and stimulate the cell’s natural capacities to redirect its own fate by integrating accurate extracellular signals. This is at the heart of Histide’s groundbreaking approach of addressing diseases called Recoding Therapeutics™, that goes beyond traditional cell, gene or RNA based therapies. Histide has a technological breakthrough with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics.
Histide™ has created an innovative platform of CRM™-based complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins, healthy or diseased, and at contrasted differentiation stages, ranging from stem cells to specialized mature cells.
In contrast to previously developed gene therapies or RNA based therapies, Histide™ technology has the major advantage of not requiring the introduction of foreign molecules inside the cell which may be irreversibly harmful to its functioning.
Recoding Therapeutics™ are instead an extracellular technological approach based on cell’s natural mechanisms of sensing and processing microenvironmental signals to adapt its fate accordingly. This allows for a precise and fine functional tuning that offers a master control over the cell biology.
Recoding Therapeutics™ are the closest to the natural cell physiology, hence, providing significantly improved safety and efficacy. They have the potential to address a wide range of altered cell conditions and diseases through the regeneration and healing of a large majority of the human body tissues.
As first applications, the CRM™ were shown to regenerate more than twelve types of tissues and to heal several types of neoplastic diseases by recoding the tumor cells into healthy and physiologically functional cells.
Cell Recoding Molecules™ are therapeutic agents characterized by a molecular weight of less than 15,000 Daltons with the capacity to activate at least one growth factor receptor. They can be grafted or not to various microenvironmental mimics or devices. The first generation of CRM™ developed by Histide are the Cell Recoding Peptides (CRP™).
Histide™ has a library of more than 150'000 CRP™ developed on the basis of more than 27 “core sequences” allowing specific non-covalent interactions with target cell receptors. A particular “core sequence” has been established for directing each cell lineage. Histide’s CRP™ library is divided into 6 distinct classes based on their rational design.
Histide™ has developed a broad, solid and disruptive intellectual property portfolio covering accurately every aspect of Histide's™ technology surrounding the CRM™ to ensure protection over the inventions and to secure their full potential and value as drivers of Histide’s overall Recoding Therapeutics™ platform.
A fully integrated patent strategy has been built to address each stage of the CRM™ discovery and development process :
Histide’s pipeline of investigational Recoding therapeutics™ is focused in 5 Strategic Therapeutic Areas :
Histide’s large & disruptive Technology Platform, protected by a strong & broad Patent Portfolio, will now explore the use of this innovative approach with the help of strong partners for each potential indication in pharmaceutical and other fields.
Histide is following a proven business model, teaming up with strong partners to maximize the potential of this impressive technology platform.
Histide AG
Chaltenbodenstrasse 8
8834 Schindellegi - Switzerland
Office: +41 43 888 2577
